TAK vs. GSK, GMAB, ZTS, ALNY, HZNP, REGN, BGNE, VRTX, BMRN, and SNY
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include GSK (GSK), Genmab A/S (GMAB), Zoetis (ZTS), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), Regeneron Pharmaceuticals (REGN), BeiGene (BGNE), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Sanofi (SNY). These companies are all part of the "pharmaceutical preparations" industry.
Takeda Pharmaceutical vs.
GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
13.2% of GSK shares are owned by institutional investors. Comparatively, 2.1% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, GSK had 22 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 27 mentions for GSK and 5 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.58 beat Takeda Pharmaceutical's score of 0.26 indicating that GSK is being referred to more favorably in the media.
GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
GSK received 699 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. However, 57.14% of users gave Takeda Pharmaceutical an outperform vote while only 56.79% of users gave GSK an outperform vote.
GSK has a net margin of 47.85% compared to Takeda Pharmaceutical's net margin of 7.91%. GSK's return on equity of 43.27% beat Takeda Pharmaceutical's return on equity.
GSK pays an annual dividend of $1.36 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays an annual dividend of $0.27 per share and has a dividend yield of 1.7%. GSK pays out 16.4% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 35.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
GSK has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Takeda Pharmaceutical has a consensus price target of $24.67, indicating a potential upside of 52.17%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.
Summary
GSK beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Takeda Pharmaceutical Competitors List
Related Companies and Tools
